Clinical evaluation of the novel, UNI-directional, PD-103 civasheet for pancreatic cancers
Ended Project Grant Awarded Last action
- Award ID
- R44CA210770
- Recipient
-
Civatech Oncology, Inc. UEI NCJMMLLMRND9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,198,271
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Morrisville, NC, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,017,318 | |
| Amendment | $1,117,042 | |
| Amendment | $1,864,846 | |
| Amendment | $1,864,846 | |
| Amendment | $570,035 | |
| Amendment | $1,464,585 | |
| Original award | $299,599 |
Quick answers
Who received award R44CA210770?
R44CA210770 was awarded to Civatech Oncology, Inc. by National Cancer Institute (National Institutes of Health) on September 13, 2016.
How much is award R44CA210770 worth?
$8,198,271 has been obligated on R44CA210770.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award